Effectiveness of disease management programs in depression: A systematic review

被引:169
作者
Badamgarav, E
Weingarten, SR
Henning, JM
Knight, K
Hasselblad, V
Gano, A
Ofman, JJ
机构
[1] Cerner Co, Zynx Hlth, Beverly Hills, CA 90212 USA
[2] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
[3] Duke Univ, Duke Clin Res Inst, Durham, NC USA
[4] Cedars Sinai Hlth Syst, Dept Med, Los Angeles, CA USA
关键词
D O I
10.1176/appi.ajp.160.12.2080
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The authors systematically evaluated the published evidence to assess the effectiveness of disease management programs in depression. Method: English-language articles on depression were identified through a MEDLINE search for the period from January 1987 to June 2001. Two reviewers evaluated 16,952 published titles, identified 24 depression disease management programs that met explicit inclusion criteria, and extracted data on study characteristics, interventions used, and outcome measures. Pooled effect sizes were calculated by using a random-effects model. Results: Pooled results for disease management program effects on symptoms of depression showed statistically significant improvements (effect size=0.33, N=24). Programs also had statistically significant effects on patients' satisfaction with treatment (effect size=0.51, N=6), patients' compliance with the recommended treatment regimen (effect size=0.36, N=7), and adequacy of prescribed treatment (effect size=0.44, N=11). One program with an explicit screening component showed significant improvement in the rate of detection of depression by primary care physicians (effect size=0.66); two other programs lacking a screening component showed small nonsignificant improvements in the detection rate (effect size=0.18). Disease management programs increased health care utilization (effect size=-0.10, N=8), treatment costs (effect size=-1.03, N=3), and hospitalization (effect size= 0.20, N=2). Conclusions: Disease management appears to improve the detection and care of patients with depression. Further research is needed to assess the cost-effectiveness of disease management in depression, and consideration should be given to more widespread implementation of these programs.
引用
收藏
页码:2080 / 2090
页数:11
相关论文
共 59 条
[31]  
Light R. J, 1984, SUMMING SCI REVIEWIN
[32]  
Lin EHB, 1999, AM J PSYCHIAT, V156, P643
[33]   Multifaceted shared care intervention for late life depression in residential care: randomised controlled trial [J].
Llewellyn-Jones, RH ;
Baikie, KA ;
Smithers, H ;
Cohen, J ;
Snowdon, J ;
Tennant, CC .
BMJ-BRITISH MEDICAL JOURNAL, 1999, 319 (7211) :676-682
[34]   Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study [J].
Murray, CJL ;
Lopez, AD .
LANCET, 1997, 349 (9064) :1498-1504
[35]  
ORMEL J, 1993, ARCH GEN PSYCHIAT, V50, P759
[36]  
Panzarino PJ, 1998, J CLIN PSYCHIAT, V59, P11
[37]   Screening for depression in adults: A summary of the evidence for the US Preventive Services Task Force [J].
Pignone, MP ;
Gaynes, BN ;
Rushton, JL ;
Burchell, CM ;
Orleans, CT ;
Mulrow, CD ;
Lohr, KN .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (10) :765-776
[38]  
*PUBL HLTH SERV AG, 1993, AHCPR PUBL
[39]  
RICE DP, 1995, BRIT J PSYCHIAT, V166, P34
[40]   THE FILE DRAWER PROBLEM AND TOLERANCE FOR NULL RESULTS [J].
ROSENTHAL, R .
PSYCHOLOGICAL BULLETIN, 1979, 86 (03) :638-641